Navigation Links
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
Date:12/8/2008

cal programs include MT203, which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy and intended utilization of our product candidates and the development of our BiTE antibody technology. You are urged to consider statements that include the words "may," "potential," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, and the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data. These factors and others are more fully discussed in Micromet's Qu
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... compliance, quality systems, analytical testing, education and consulting services for the medical ... medical device products/processes development, design control, validation, quality assurance and regulatory compliance. ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Markets and Companies" to their offering. ... markets based on technologies and applications. The report ... basis for estimation of markets. Technologies include array ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:9/2/2015)... 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. The ... fluorescence in situ hybridization (FISH), comparative genomic ... includes application of nanobiotechnology, microarrays, real-time polymerase ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3
... Inc. (NYSE: CRY ), and BioForm Medical, Inc. ... a CE Mark for the use of CryoLife,s,BioGlue Surgical ... a reconstructive plastic surgery procedure. The CE,Mark approval allows ... BioGlue will be distributed by CryoLife,s partner BioForm ...
... Environmental,Tectonics Corporation,s (Amex: ETC ) ("ETC" or ... of seven (7) BARA-MED(R) XD,Monoplace Hyperbaric Chambers to ... associated with Haelen Hyperbarics., ETC is delighted ... of,physician operated Hyperbaric Oxygen Therapy (HBOT) clinics. Haelen,Hyperbarics ...
... Also Completes FDA Submission for Removal of Clinical ... Genta,Incorporated (OTC Bulletin Board: GNTA) announced that the ... patents from the European,Patent Office for its pipeline ... to composition of matter for the tesetaxel drug,substance ...
Cached Biology Technology:CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 2CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 3CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 4Environmental Tectonics Corporation's BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers 2Environmental Tectonics Corporation's BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 4
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... researchers say they have found ,missing heat, in the climate ... or stopped over the past decade. , Observational data ... cent of the planet with Polar regions and parts ... scientist at the University of York, and Robert Way, a ...
... (November 13, 2013) Scientists from the New York ... Medical Center (CUMC) have used stem cells created from ... diabetesWolfram syndrometo elucidate an important biochemical pathway for beta-cell ... colleagues were published today in Diabetes . ...
... provider of scientific, technical and medical information products and services, ... the first full open access journal within the Biochimica ... BBA Clinical will focus on translating molecular ... is a biomedical journal dedicated to publishing research on ...
Cached Biology News:'Missing heat' discovery prompts new estimate of global warming 2Human stem cells used to elucidate mechanisms of beta-cell failure in diabetes 2Human stem cells used to elucidate mechanisms of beta-cell failure in diabetes 3Elsevier's Biochimica et Biophysica Acta (BBA) journal series adds open access journal: BBA Clinical 2
... and ES1301 mutS are mismatch repair minus ... strains prevents repair of the newly synthesized ... efficiencies and making them helpful in such ... II Mutagenesis Systems. Both ES1301 and BMH ...
propidium iodide *1.0 mg/mL solution in water*...
Applications: (+) Immunocytochemistry and immunohistochemistry...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: